CJC-1295 and Ipamorelin: how the combination is studied
5 min read · Updated May 2026
A recurring theme in growth-hormone-axis research is studying two peptides that act through different receptors on the same pituitary cells: a GHRH analogue and a growth-hormone secretagogue. CJC-1295 and Ipamorelin are the most common pairing for this kind of work.
Research use only. Both peptides are supplied strictly for in-vitro laboratory research. This page does not describe dosing, administration, stacking for use, or any human or animal application, and makes no therapeutic claims.
Two receptors, one model
- CJC-1295 is a GHRH (1-29) analogue that activates the GHRH receptor.
- Ipamorelin is a selective agonist at the ghrelin / GH-secretagogue receptor (GHSR-1a).
Because they engage distinct receptors, studying them in the same experimental system lets researchers compare convergent versus independent signalling — for example, whether downstream responses are additive, synergistic, or unrelated under defined exposure conditions. As always, observed effects depend on concentration, timing and model design, and the work characterises receptor signalling rather than physiological outcomes.
Typical research questions
- How do GHRH-receptor and GHSR-1a signalling interact in pituitary-derived cells?
- Do transcriptional or second-messenger responses differ when both receptors are engaged?
- How does selectivity (e.g. ipamorelin's lack of ACTH/cortisol activation) shape combined-signalling experiments?
How they are supplied
CJC-1295 and Ipamorelin are supplied as separate lyophilised vials, each with a Certificate of Analysis, stored refrigerated at 2–8°C.